本帖最后由 老马 于 2012-1-13 21:20 编辑 9 P% Q5 C8 K7 U
, J- s( c( ?- E/ c爱必妥和阿瓦斯丁的比较3 e5 z" z5 [+ k5 i) a. O
; }! a3 g8 L+ v) h; ^
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* t! ~7 y: [# Y
4 R$ z0 T5 J; J, _
3 x; Y. q( p) p/ Xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
H0 R( |9 `; q8 g2 b==================================================
! }* l; z T3 ?! S1 q6 AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)( P8 `5 w, E) B1 w% Q4 v2 ~. F
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ `' t/ g( G* `% p1 u3 PResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 ^" u9 a! {8 H9 v! x! r
|